NL-OMON45553撤回2 期
A multisite randomized clinical trial evaluating BP1.3656 vs placebo for alcohol use disorder treatment. - BP15-01
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Male of female with moderate or severe DSM-5 alcohol use disorder (based on the alcohol use disorders section of the MINI plus);
- •2. Ages 18-65;
- •3. Low to moderate alcohol withdrawal symptoms: CIWA-Ar scale < 10 at baseline assessment;
- •4. Normal weight: 18 kg/m2 * 35 kg/m2;
- •5. Excessive alcohol use: number of heavy drinking days (* 60g/day in men and * 40 g/day in women) * 15 during 30 days prior to screening and * 7 during the 2 weeks between screening and baseline;
- •6. Treatment-seeking, treatment goal: reduced drinking or abstinence;
- •7. If fertile, both males and females must agree to use effective birth control, agree to continue this method for the duration of the study up until 21 days after study completion and be negative to serum pregnancy test performs at the screening visit. Females should not be breastfeeding.;
- •8. Adequate social support according to the investigator to comply with the study requirements described in the protocol (e.g. transportation to and from the trial site, self-rating scales, drug compliance, scheduled visits, etc.);
- •9. Voluntarily expressed willingness to participate in the study, understanding protocol procedues and having signed and dated an informed consent prior to the start of the protocol required procedures while not intoxicated (BAC < 0.05);
- •10. Willingness to receive psychosocial support.
排除标准
- •1. History of delirium tremens, epilepsy, or withdrawal seizures;
- •2. Clinical depression or suicidality; Beck Depression Inventory (BDI) * 16 and suicidality (item G * 0);
- •3. Recent illicit drug use, i.e. cannabis, cocaine, amphetamine or opiods;
- •4. Clinically significant cardiovascular, hematologic, severe hepatic impairment or (FLTs > 3 ULN), renal (stage 2 and 3 according to international classification of renal kidney disease), neurological, endocrinological abnormalities or abnormal clinical laboratory results (in most cases > 3 ULN)
- •5. History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes;
- •6. HIV positive; HCV postive; HBsAg postive;
- •7. History of psychosis, or current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression or organic brain syndrome unrelated to alcohol abuse;
- •8. Physical dependence on sedatives or hypnotics that requires pharmacologically supported detox;
- •9. Receiving ongoing alcohol use disorder medication (e.g. Baclofen);
- •10. Other active clinically significant illness, which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study participation, such as Parkinson*s disease;
- •11. Known history of syncope, arrhytmia, myocardial infarction or any known significant ECG abnormality;
- •12. Known hypersensitivity to the tested treatment including active substance and excipients;
- •13. Participation in clinical trials and receipt of investigational drug(s) during previous 60 days, except as explicitly approve by the principal investigator;
- •14. Insufficient medical insurance according to local regulations;
- •15. Pregnant woman or a pregnancy detected with a positive serum pregnancy test performed at the screening visit or lactating women;
- •16. Male subject who want to conceive a child during the duration of the study up until 21 days after study completion.
研究者
相似试验
终止
不适用
Randomized, pilot, multicenter clinical study in Brazil to assess the feasibility ofImprovement of static lung compliance by different Positive End Expiratory Pulmonary Pressure titration methods in patients with Adult Respiratory Distress SyndromeRBR-9b7jbxmHospital Nereu Ramos
已完成
不适用
Multicenter randomized controlled trial based on balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Sub study (MR BPA Sub Study)Chronic thromboembolic pulmonary hypertension (CTEPH)JPRN-UMIN000021466Department of Cardiology, Keio University School of Medicine60
进行中（未招募）
1 期
A clinical study investigating the efficacy, tolerability and safety of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with a diagnosis of bipolar I disorderEUCTR2017-002190-20-HROtsuka Pharmaceutical Development & Commercialization, Inc.333
进行中（未招募）
1 期
A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I DisorderEUCTR2017-002222-20-PLOtsuka Pharmaceutical Development & Commercialization, Inc.322
进行中（未招募）
1 期
A clinical study investigating the efficacy, tolerability and safety of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with a diagnosis of bipolar I disorderTreatment of Manic Episodes Associated with Bipolar I DisorderMedDRA version: 20.0Level: LLTClassification code 10068455Term: Bipolar I disorder, hypomanicSystem Organ Class: 100000004873EUCTR2017-002222-20-BGOtsuka Pharmaceutical Development & Commercialization, Inc.322